

# Approches de protéomique spatiale pour l'étude des mécanismes moléculaires de pathologies

**Joanna Bons**

Laboratoire de Spectrométrie de Masse BioOrganique (LSMBO)  
IPHC, UMR 7178, CNRS – Université de Strasbourg  
[j.bons@unistra.fr](mailto:j.bons@unistra.fr)

*Workshop Transcriptomique et Protéomique spatiale : des avancées technologiques pour la recherche en santé, 28/04/2026*


# We are interested in PROTEINS, the workhorses of life

- Proteins = **functional** and **dynamic** units, carrying most cellular functions
- **Post-translational modifications** = critical for protein functions, activities, localizations, and interactions
  - *They cannot be predicted from transcriptomics or metabolomics data*
  - *In humans, ~20,000 genes  $\rightarrow$  >1 million predicted proteoforms!*




<https://gaelmcgill.artstation.com/projects/Pm0JL1>

- **Poor correlation** between mRNA and protein abundance



Translation rate vs degradation rate



Schwanhäusser B et al., Nature, 2011

- Many **biomarkers** and **drug targets** are proteins!

# Two routes to study the proteome



Gael McGill

<https://gaelmcgill.artstation.com/projects/Pm0JL1>

Proteome

## Antibody-based analysis

IHC

SomaScan

Olink

CyTOF

MALDI HiPLEX-IHC

**Targeted proteomics**

## Mass Spectrometry-based analysis



LC-MS/MS

*Bottom-up proteomics*

MS imaging

**Untargeted proteomics**

# 25 years of progress towards higher sensitivity & throughput



Sample preparation  
→ Miniaturization  
→ Automation




Data analysis tools  
→ AI-prediction tools



Confidence PTMs


# Bottom-up proteomics for identification and quantification



Bottom-up proteomics tells us

- ✓ What proteins are present
- ✓ In what quantity proteins are present

# But spatial information is missing




Bottom-up proteomics tells us

- ✓ What proteins are present
- ✓ In what quantity proteins are present

But **not** where proteins are **localized**

# We need to analyze proteins *spatially*



- Mapping proteins within their native environment by capturing both protein **identity and location** profiles within defined structures

## Editorial

<https://doi.org/10.1038/s41592-024-02565-3>

## Method of the Year 2024: spatial proteomics

 Check for updates

**Approaches for profiling the spatial proteome in tissues are the basis of atlas-scale projects that are delivering on their promise for understanding biological complexity in health and disease.**

**H**umans by nature are inquisitive. We love to explore, and as we do, we make maps. Perhaps it is then not surprising that we find ourselves in an age of atlas-building as we explore the incredible complexity of biological systems with cutting-edge methods to better understand how cells, tissues, organs and organisms connect structure and function.

In the spirit of exploring and mapping biological complexity, we have chosen spatial proteomics as our Method of the Year for



field of spatial proteomics. The piece further describes how generating large atlases will help reveal the intricacies of complex tissues and pave the way for precision medicine. It ends with a discussion of technological developments that will help move the field forward, briefly commenting on the role artificial intelligence may play in the future.

Computational tools for spatial proteomics are the focus of the second Comment, from Yuval Bussi and Leeat Keren<sup>5</sup>. These authors note that current image processing and analysis workflow are well defined but fragmented, with various steps happening back to back rather than in an integrated fashion. They envision a future for the field where image processing and analysis steps work in concert for improved biological discovery.


The third Comment<sup>6</sup>, from Daniela Quail and Logan Walsh, discusses how spatial proteomics has revolutionized cancer research,

# Spatial proteomics

- Mapping proteins within their native environment by capturing both protein **identity and location** profiles within defined structures


## Why is it important?

- Biological processes are spatially arranged
- Protein function may depend on its location
- Connecting molecular functions and cellular architecture/tissue heterogeneity
- Necessary to better understand physiology and diseases







# Spatial proteomics operates across multiple scales

## Complexity



## Resolution



### **Tissue**

Whole tissue or regions

### **Region/Micro-environment**

Defined regions, specific niches

### **Cell**




Different cell populations or individual cells

### **Subcellular**

Compartments/organelles, protein complexes

# Spatial proteomics operates across multiple scales

## Resolution



### Tissue

Whole tissue or regions



### Region/Micro-environment

Defined regions, specific niches



### Cell

Different cell populations or individual cells




### Subcellular

Compartments/organelles, protein complexes

# Strategies for subcellular proteomics



## Compartment isolation by differential centrifugation (LOPIT-DC\*)

→ Currently being implemented @LSMBO



# Spatial proteomics operates across multiple scales

## Resolution



### Tissue

Whole tissue or regions



### Region/Micro-environment

Defined regions, specific niches



### Cell

Different cell populations or individual cells



### Subcellular

Compartments/organelles, protein complexes

# Single cell proteomics

Christine Carapito




## Isolation

## Lysis

## Liquid chromatography

## Tandem mass spectrometry

## Data processing



CellenOne (Cellenion)  
Cell sorting & sample  
preparation robot





TimsTOF Ultra (Bruker → September 2023)  
Orbitrap Astral (Thermo → August 2024)  
DIA-PASEF & FAIMS-DIA MS/MS

>5000 unique proteins on single HeLa cells



# Spatial proteomics operates across multiple scales

## Resolution



### Tissue

Whole tissue or regions

### Region/Micro-environment

Defined regions, specific niches

### Cell

Different cell populations or individual cells

### Subcellular

Compartments/organelles, protein complexes


# Spatial proteomics operates across multiple scales

## Resolution




### Tissue

Whole tissue or regions



### Region/Micro-environment

Defined regions, specific niches



### *Case study:*


**Investigate how the extracellular matrix is remodeled  
in lung squamous cell carcinoma (LSCC)**

# Stroma contributes to CIAC development

Thea Tlsty  
Project Leader  
University of California at San Francisco



UCSF  
University of California  
San Francisco



Institute for  
Systems Biology  
Professionally Science, Empowering Life

Research  
Institute  
McGill University  
Health Centre

Barts  
Cancer Institute  
Queen Mary University of London



McGill  
UNIVERSITY


VANDERBILT UNIVERSITY

מכון ויצמן למדע  
WEIZMANN INSTITUTE OF SCIENCE



CANCER RESEARCH UK  
CAMBRIDGE INSTITUTE

## Chronic inflammation-associated cancer (CIAC)




Tlsty T.D. and Gascard P., 2019, *Science*

- Address the **unmet clinical needs of CIACs** – stromal-targeted therapy for prevention and intervention
- We need to gain insights into **extracellular matrix (ECM) proteome remodeling**

# Tumor-specific marker candidates in LSCC

## Prospective sample collection



Tumor  
Matched  
Normal

From 10 patients with  
lung squamous cell  
carcinoma (LSCC)

## ECM proteins




Enriched,  
solubilized

## Digestion





Peptide mixture


## Liquid chromatography




## Tandem mass spectrometry



## Quantification & statistics




## In-depth ECM proteome profiling




Total = 1,802  
quantifiable protein groups  
( $\geq 2$  unique peptides)

## Tumor vs Matched Normal




# Conserved ECM remodeling signature in LSCC


## Basement membrane in Lung SCC




## Small leucine-rich proteins in Lung SCC




## Type I collagen in Lung SCC



## Normal ECM



## Tumor ECM



ECM remodeling in LSCC



# SERPINH1/Hsp47 as a potential biomarker for CIACs?

Tumor vs Matched Normal  
(same patient)

Lung Oesophagus Stomach

SERPINH1 -

Log<sub>2</sub>(T vs MaN) 1.23 1.44 0.79

Q-value 8 e-15 8 e-2 2 e-2

Profiling of SERPINH1/Hsp47  
by immunofluorescence:


## Dramatic increase

in cancer-associated fibroblasts (CAF) in


- **Lung** Squamous Cell Carcinoma, LSCC
- **Oesophageal** Adenocarcinoma, EAC

## Detection of **SERPINH1/Hsp47** In Lung

Normal Lung Bronchi




LSC Carcinoma (CIAC)




## Detection of **SERPINH1/Hsp47** In Oesophagus

Normal Oesophagus






EA Carcinoma (CIAC)



# Spatial proteomics operates across multiple scales

## Resolution



### Tissue

Whole tissue or regions

### Region/Micro-environment

Defined regions, specific niches

### Cell

Different cell populations or individual cells

### Subcellular

Compartments/organelles, protein complexes

**Mass spectrometry imaging as a powerful tool to study tissues or regions of interest in pathologies**

# MALDI-Mass spectrometry imaging (MSI) workflow

*MALDI: Matrix-assisted laser desorption ionization*

**Tissue section**  
(~10  $\mu\text{m}$ )

**MALDI matrix deposition**


**MALDI ionization**

**MS Imaging**






**Data processing**

One spectrum  
per pixel

Distribution map  
of one analyte




Conductive ITO slide




- ✓ **Label-free**
- ✓ ***In situ* co-localization of analytes**

Matrix depends on the investigated analytes and polarity.

For instance:  $\alpha$ -cyano-4-hydroxycinnamic acid (CHCA), sinapinic acid



CHCA




Sinapinic acid

**Today**

- 10 kHz, up to 20 pixel/s
- **Spatial resolution:**
  - routine: 20  $\mu\text{m}$
  - down to 5  $\mu\text{m}$  (~single cell)

# Spatial proteomics by bottom-up MALDI-MSI


- **On-tissue protein digestion** compatible with FFPE and fresh-frozen samples
- Additional steps need to be performed beforehand:
  - **FFPE samples:** deparaffinization → antigen retrieval → enzymatic digestion
  - **Fresh-frozen samples:** lipid and salt washing → enzymatic digestion




Today, **~10s** of proteins identified *in situ* by **bottom-up MALDI-MSI**

# MSI-guided spatial proteomics

## 1) MALDI-MSI experiment to determine regions of interest – **IMAGING**



## 2) Microsampling followed by LC-MS/MS for in-depth spatially-resolved protein identification – **PROFILING**






→ **Several 1000s of proteins identified by high-throughput LC-MS/MS**

*Other excision techniques are available.*

*Adapted from Lopez A, Hummon AB, Anal Methods, 2026*

# Spatial proteomics operates across multiple scales

## Resolution



### Tissue

Whole tissue or regions

### *Case study:*

**Unveil the molecular heterogeneity of  
glioblastoma tumor microenvironment**

Duhamel M., Fournier I., Salzet M., *et al.*, *Nat Commun*, 2022



→ MALDI MSI approaches under development @LSMBO

# Glioblastoma heterogeneity

- Glioblastoma
  - Main malignant primary brain tumor
- Survival:
  - Median survival ~12-16 months
  - ~5% of patients survive more than 5 years
- **Highly heterogeneous tumors:**
  - Across microenvironments and within each microenvironment
  - Poor patient stratification and discrepancies in patient survival

Spatial proteomics of clinical samples of glioblastoma to characterize the molecular heterogeneity of glioblastoma tumors


## Tumor microenvironment of glioblastoma



Adapted from Perdyan A *et al.*,  
*F1000Research*, 2022

# MSI-guided spatial proteomics of glioblastoma

46 glioblastoma patients of varying survival




➤ Correlation between  $m/z$  features and histological annotations

➤ Segmentation maps identify 3 main molecular clusters

➤ Microextraction followed by LC-MS/MS analysis to determine proteomic profiles

# Identification of three molecular regions in glioblastoma

Proteins with differential profiles across the three regions:



Neurotransmission and synaptogenesis  
(neurogenesis and axon guidance)

Tumorigenesis (MAPK3, PRKCA, CRMPs, GAP43, Tau)

RNA processing and metabolism, tumor growth  
(HDGF, DRG2), virus infection

Bad prognosis indicators (EIF2AK2, ZC3HAV1)

Immune infiltration (microglial activation, immune  
system activation), iron transport

*Histology: intense proliferation of capillary endothelial  
cells with inflammation and hemorrhage*

- Integration with survival data → identification of 5 prognostic survival markers
- Identification of specific molecular phenotype of the glioblastoma tumors informing on the intratumoral molecular heterogeneity



# Conclusions

---

**Spatial proteomics using mass spectrometry** = powerful approaches:

- ✓ Map proteins *in situ* from **fresh** and **FFPE** tissues – from 10s (bottom-up MALDI) to several 1000s (microsampling coupled to LC-MS/MS) proteins.
- ✓ Uncover regionally-defined molecular profiles, **at different and complementary scales**, down to 5  $\mu\text{m}$  resolution.

**Molecular heterogeneity** is more important than histological heterogeneity.

Spatial proteomics enables

- Gaining insights into **proteome complexity** and **processes/signaling pathways** associated with **pathogenesis** and **progression, notably in cancer**.
- Identifying **novel biomarker candidates** and potential **therapeutic targets**.



**Thank you for your attention!**

**Questions?**